Otto Loewi Forschungszentrum

Research focus: Metabolism and the gut

PI: Gunther Marsche

Focus: Our laboratory investigates the roles of high-density lipoproteins (HDL) in inflammatory and allergic diseases. Beyond reverse cholesterol transport, HDL exert critical immunomodulatory functions essential for vascular health. However, chronic inflammation induces structural remodeling and post-translational modifications that impair HDL’s protective capabilities, rendering particles dysfunctional or pro-inflammatory. We aim to unravel the molecular mechanisms driving this functional decline by dissecting HDL's composition and biological activities. To translate these insights into therapies, our research focuses on apolipoprotein A-I (apoA-I) mimetic peptides - synthetic constructs that replicate native apoA-I’s anti-inflammatory and cardioprotective actions - to restore HDL functionality in inflammatory disease states.

Projects

Apolipoprotein AI mimetic peptide lipid assemblies

  • HDL particles are highly complex, and their composition and function are significantly altered in inflammatory diseases. This creates a need to restore or even enhance the impaired functionality of HDL in such conditions. Apolipoprotein A-I (apoA-I), the most abundant protein in HDL, is primarily responsible for its well-recognized anti-inflammatory properties. In this project, we are investigating the structure and function of artificially synthesized peptides, ranging from 18 to 37 amino acids in length, that mimic various activities of full-length apoA-I when lipidated
  • Project duration: 2022-2026
  • Funding body: FWF
  • Project Partners*: Ruth Prassl (Medical University of Graz), Mounir Tarek (Laboratory of Theoretical Physics and Chemistry, University of Lorraine in France)

 

Division of Pharmacology

Gunther Marsche 
T: +43 316 385 74128